Conditional approval in Europe for Shire rare disease therapy

26 April 2017
2019_biotech_test_vial_discovery_big

Rare disease specialist Shire (LSE: SHP) has been granted conditional approval in the European Union for Natpar (parathyroid hormone), the company announced today.

The drug, which is approved in the USA under the trade name Natpara, is a hormone therapy indicated as an adjunctive treatment for adult patients with chronic hypoparathyroidism.

Hypoparathyroidism is a rare endocrine disease which results from from low levels of a particular hormone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology